Introduction
Systemic mastocytosis (SM) is a disease characterized by a pathologic increase in mast cells in skin, bone marrow, and internal organs, such as liver, spleen and lymph nodes. 1, 2 SM is associated with gain-of-function mutations involving the tyrosine kinase domain of c-kit (most commonly D816V). The current classification of mastocytosis (World Health Organization) divides the disease into seven categories; cutaneous mastocytosis, systemic indolent mastocytosis, systemic mastocytosis with an associated hematologic clonal nonmast cell disease, systemic aggressive mastocytosis, mast cell leukemia, mast cell sarcoma, and extracutaneous mastocytoma. 3 Although SM behaves as an indolent myeloproliferative disease in most patients, it can also present as aggressive disease that requires mast cell eradication.
In the absence of a curative option, therapy of SM is generally symptomatic, using H1 and H2 antihistamine blockade, oral disodium cromoglycate, and glucocorticoids. 4 Studies examining the effect of the tyrosine kinase inhibitor imatinib have shown that this drug is ineffective against mast cells carrying the D816V c-kit mutation. In the absence of a successful mast cell cytoreductive chemotherapy, other therapeutic options such as bone marrow transplantation need to be considered.
Limited experience using allogeneic HCT with fullintensity conditioning for SM has been reported. [5] [6] [7] [8] Since advanced SM is typically resistant to chemotherapy, we selected a low-intensity but highly immunosuppressive conditioning regimen 9, 10 to reduce transplant-related mortality while allowing complete engraftment of the donor's immune cells. In this prospective study, we evaluated the safety, engraftment, and possibility of controlling advanced SM by induction of a graft-versus-mast cell (GvMC) effect following allogeneic nonmyeloablative HCT.
Materials and methods
After obtaining informed consent, three patients were enrolled into the local institutional review board approved protocol 01-H-0010. Patient characteristics and transplant outcomes are listed in Table 1 . Mutational analysis of c-kit gene was performed as described. 9 The preparative regimen consisted of intravenous cyclophosphamide 60 mg/kg on days À7 and À6 followed by fludarabine 25 mg/m 2 on days À5 to À1. On day þ 0, patients received unmanipulated, G-CSF-mobilized peripheral blood hematopoietic stem cells from an HLAidentical sibling. 10, 11 GvHD prophylaxis consisted of cyclosporine A (CSA) and mycophenolate mofetil (MMF) as previously described.
11 MMF was administered orally at the dose of 1 g twice daily starting on day 0. Decisions regarding post transplantation immunosuppression withdrawal and lymphocyte infusion were based on the degree of engraftment of donor T cells and disease status. Donorrecipient chimerism in both myeloid and T cell lineages was assessed by PCR of polymorphic VNTR or STR. 10, 11 Patients with full-donor T cell chimerism (490%) by day þ 30 continued to receive full-dose immunosuppression (CSA/MMF) until day þ 60; thereafter, if GvHD remained absent, immunosuppression was tapered and discontinued by day þ 100. Patients with disease progression and mixed T cell chimerism by day þ 30 had their immunosuppression tapered more rapidly. Infection prophylaxis and other supportive care were provided according to the institutional standard.
10,12

Results
Case 1
A 42-year-old male was diagnosed with SM in 1996 after 2-year history of episodic flushing, headache, and skin rash. He also had a history of anaphylaxis for which he carried an Epipen. He developed progressive disease with multiple neurological complications due to local expansion of dense collections of mast cells including cord compression at the level of thoracic spine and tumors in the left orbit with loss of central vision, as well as worsening cytopenias (WBC 3.300/ml, Hb 8.7 g/dl, platelet 89 000/ml), hepatosplenomegaly and lymphadenopathy. A bone marrow (BM) biopsy showed diffuse infiltration of abnormal mast cells without evidence of an associated clonal hematologic disease. He was considered to have an aleukemic variant of mast cell leukemia. Prior to receiving conditioning for HCT, he underwent a second laminectomy due to another mastocytoma which was felt to be impinging on his spinal cord.
He tolerated the conditioning and stem cell infusion. However, on day þ 3 he developed severe nausea, vomiting, and flushing and required treatment including epinephrine in the ICU for the next 2 weeks. He achieved 100% donor T cell engraftment by day þ 60, although myeloid chimerism remained 40-50%.
He experienced three separate episodes of acute GvHD flare, each of which was accompanied by mast cell mediator symptoms including flushing and nausea requiring epinephrine injections. The first episode occurred on day þ 45 and was associated with grade 3 skin GvHD. Two subsequent episodes occurred on day þ 65 associated withgut GvHD and on day þ 100 associated with recurrence of skin GvHD. Both mast cell mediator-release symptoms and GvHD promptly responded to steroids. We considered this to be consistent with alloimmune reactions (GvMC) resulting in mast cell mediator release rather than spontaneous release of mast cell mediators triggering GvHD.
Despite GvHD, the mastocytosis progressed with increasing serum tryptase, splenomegaly, and pancytopenia. He expired on day þ 170 due to progressive mastocytosis and disseminated aspergillosis. Allogeneic stem cell transplantation for advanced systemic mastocytosis R Nakamura et al tolerated conditioning except for an allergic reaction to Mesna. She developed an engraftment syndrome around day þ 30, which promptly responded to a short course of steroids. Engraftment analysis revealed 100% donor T cells and 90% myeloid cells on day þ 30. MMF was discontinued on day þ 60 and CSA was tapered. This was followed by acute grade II skin GvHD on day þ 78. After steroid treatment, the GvHD and the original skin lesions started to improve (Figure 1b and d) . Although blood counts fell temporarily (ANC 160/ml, platelet count o10,000/ml), and a BM biopsy revealed persistent mast cells and dysplastic hematopoiesis (Figure 1f ), complete withdrawal of immunosuppression resulted in conversion to 100% donor myeloid chimerism by day þ 140. This was associated with improved blood counts and marrow appearance (Figure 1g ). The serum tryptase decreased from 150 to 78 ng/ml and she became transfusion independent (Figure 2 ). She remained well and symptom free until she presented 39 months post transplant with chloromas in her uterus and right temporal region. The tryptase level at relapse was around 60-70 ng/ml.
The clinical response after withdrawal of immunosuppression and GvHD supports the presence of a GvMC effect. However, persistent mast cells and late extramedurally relapse with chloromas indicates limited ability of the transplant approach to completely eradicate disease.
Case 3
A 45-year-old male was diagnosed with SM in 1999 with a history of unexplained rashes, episodic flushing and abdominal cramping. His white count was elevated at 25 000/ml with 36% eosinophils. Computerized tomography revealed hepatosplenomegaly, and extensive mediastinal and retroperitoneal adenopathy. His bone marrow biopsy showed myeloproliferative disorder with significant mast cell infiltrates. He received a trial of interferon alpha for 1 year without efficacy.
He underwent a nonmyeloablative HCT in 2002. His post transplant course was unremarkable. He achieved full donor T cell chimerism by day 30, but mixed myeloid chimerism persisted despite withdrawal of immunosuppression. On day þ 118, a donor lymphocyte infusion (DLI) of 5 Â 10 6 CD3 cells/kg was given to boost a graft-versusmarrow effect. This led to an episode of grade 2 acute gut GvHD but resulted in conversion to full donor myeloid chimerism. By 6 months post transplant the serum tryptase had fallen from 889 to 404 ng/ml and the eosinophil count decreased from 15 372/ml pretransplant to 625/ml. However, by nine months post transplant his original symptoms returned and the tryptase levels rose.
Discussion
In this pilot study, we evaluated the safety, engraftment, and possibility of controlling advanced SM by induction of a GvMC effect following allogeneic nonmyeloablative HCT. The observed regimen-related toxicity and engraftment kinetics in T cell and myeloid lineages were consistent with our previous experience with nonmyeloablative conditioning. 10, 11 While there was no transplant-related mortality in this small cohort, we experienced management challenges unique to systemic mastocytosis. Case 1 developed mast cell mediator release symptoms on day þ 3 post transplant and required ICU admission for epinephrine infusion. The triggering event for this reaction remains unclear, but most likely, the conditioning regimen, GvHD prophylaxis, medications for supportive care, and/or HCT graft infusion might have been responsible for the event. Case 2 had an unexpected allergic reaction to Mesna necessitating substitution with continuous bladder irrigation. Anticipating such a reaction, we used routine prophylactic antihistamine and avoided the use of intravenous MMF since polysorbate in the intravenous MMF formulation could be allergenic. This experience suggests that mast cell degranulation events may be triggered during conditioning and engraftment phases suggesting that monoclonal or polyclonal antibodies that are often used in HCT such as antithymocyte globulin should be used with extreme caution.
Our results demonstrate that nonmyeloablative allogeneic HCT for advanced SM results in complete donor donor lymphocyte infusion.
Allogeneic stem cell transplantation for advanced systemic mastocytosis R Nakamura et al T cell chimerism, which can lead to a GvMC effect. The presence of a GvMC effect was supported by these three cases; case 1 with distinct GvHD flare episodes associated with mast cell mediator release symptoms, case 2 with late improvement in transfusion requirements, and resolution of bone marrow findings, as well as mast cell skin lesions following withdrawal of immunosuppression and appearance of GvHD, and case 3 with late improvement of tryptase and eosinophil counts after DLI and GvHD. However, sustained remissions were not achieved in any of the patients. The relative resistance of extramedullary disease to a graft-versus-leukemia effect has been previously observed. 13, 14 More importantly, greater reduction in disease burden may be necessary to achieve better longterm control of mastocytosis. Newer therapeutic agents for SM including cladribine, [15] [16] [17] imatinib mesylate (for selected cases without c-kit codon 816 mutations [18] [19] [20] [21] [22] , and novel KIT inhibitors 23 may be considered for this purpose. Indeed, a number of novel targeted agents have demonstrated promising activity in vitro and/or in vivo against the c-kit D816V mutation believed to be the pathogenic mutation in most cases of systemic mastocytosis. [24] [25] [26] [27] [28] However, the continued importance of defining effective transplant regimens is underscored by the experience with targeted therapy in CML. Despite the success of imatinib in inducing clinical and cytogenetic remission in chronic phase CML, reservations remain regarding the lack of molecular remission in most patients and the fact that some patients relapse with ABL mutations conferring imatinib-resistance. [29] [30] [31] [32] Development of an effective targeted therapy for cytoreduction combined with less intense transplant conditioning regimens that allow graft versus tumor effects without significant transplant related mortality may prove to be an ideal treatment for aggressive systemic mastocytosis.
